Whole-genome sequencing data from the All of Us Research Program, covering 265 AML cases and 169,706 controls, identified four genes carrying statistically significant rare protein-coding variant burdens associated with acute myeloid leukemia: DNMT3A, TET2, SRSF2, and IDH2. Using the SAIGE-GENE+ set-based association framework with Bonferroni-corrected Cauchy combination p-values, these genes cleared stringent significance thresholds. Additionally, rare-variant burden scores built from Genomic Data Commons gene-sets — both AML-specific somatic mutation genes and pan-cancer somatic mutation genes — reached significance, reinforcing a shared germline-somatic architecture in blood cancer risk.
All four implicated genes are already well-established drivers of clonal hematopoiesis of indeterminate potential (CHIP), a condition in which somatic mutations accumulate in blood stem cells with age and elevate leukemia risk. What makes this preprint notable is the confirmation that germline rare variants in these same genes also carry population-level risk signals detectable in a diverse biobank — bridging somatic and germline oncology. For longevity researchers, DNMT3A and TET2 mutations are among the most common CHIP mutations found in adults over 70, making these findings relevant to aging biology broadly. Limitations are substantial: only 265 AML cases constrain statistical power, the analysis is restricted to European-ancestry participants limiting generalizability, and the design is observational rather than causal. As a preprint not yet peer-reviewed, these results require independent replication and expert scrutiny before clinical translation. Still, the work represents a meaningful incremental advance in mapping germline contributions to a deadly blood cancer.
